Loading...
Diversified Pipeline And Global Reach Will Advance Neurology Markets
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
21 Aug 25
Updated
21 Aug 25
AnalystHighTarget's Fair Value
US$20.00
76.6% undervalued intrinsic discount21 Aug
US$4.67
1Y
-12.7%7D
3.1%1Y
-12.7%7D
3.1%